Back to journals
Academic Journal

European Neuropsychopharmacology

32 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 32 psychedelic papers Blossom tracks from European Neuropsychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does European Neuropsychopharmacology carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

4papers published in 2016

+300% vs 2015

7 published by 2016

Browse papers→

Don't read as the journal's total output: only the 32 of 32 tracked psychedelic papers from European Neuropsychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does European Neuropsychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
14
Anxiety Disorders
10
Neuroimaging & Brain Measures
9
Safety & Risk Management
7
Addiction & Substance Use
5
Suicidality
3
Medicinal Chemistry & Drug Development
3
Neurocognitive Disorders
3
Other
19

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does European Neuropsychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
11
MDMA
5
LSD
4
Ketamine
3
Ayahuasca
2
DMT
2
Esketamine
1
Mescaline
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

European Neuropsychopharmacology has 32 tracked papers indexed in Blossom (2013–2026) from 220 authors, most often covering Psilocybin, MDMA and Placebo, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.

Published Papers

Open Accessindividual

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers

This double-blind randomised controlled trial (n=120) in healthy volunteers assessed how well blinding held when people received psilocybin, MDMA, or methylphenidate as an active placebo, and found blinding was generally insufficient. Functional unblinding was highest for psilocybin, moderate for MDMA, and lowest for methylphenidate.

Published
Journal
European Neuropsychopharmacology
Authors
Belinger, L., Rieser, N., Engeli, E., Becciolini, L., Clamote, M., Pribis, M., Saissi, F., Florineth, G., Hehl, N., Herdener, M., Preller, K.
Open Accessindividual

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study

This Phase IV single-arm long-term extension trial (n=183) found that the vast majority of patients with treatment-resistant depression who achieved remission with esketamine nasal spray (plus an antidepressant) did not relapse over 136 weeks of treatment, with side effects largely resolving the same day and no new safety concerns identified.

Published
Journal
European Neuropsychopharmacology
Authors
Reif, A., Anıl, Y. A., Bitter, I., Buyze, J., Frey, R., Godinov, Y., Haggström, L., Kambarov, Y., Nielsen, R., Oliveira-Maia, A., von Holt, C., Cubała, W., Young, A. H., DJ, Fu.
Open Accessmeta

Psychedelics: The pathway to implementation in the European healthcare systems

This review (2025) examines the challenges of integrating psychedelic therapies into European healthcare systems, highlighting that beyond obtaining regulatory approval, these treatments must also pass health technology assessments in individual countries, a process complicated by the lack of studies comparing psychedelics to existing treatments and the difficulty of evaluating therapies that combine drugs with psychotherapy.

Published
Journal
European Neuropsychopharmacology
Authors
Gründer, G., Mertens, L. J., Spangemacher, M., Meyer-Lindenberg, A., Jungaberle, H.
Paywallindividual

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial

This secondary analysis of an RCT comparing psilocybin therapy to escitalopram in MDD patients (n=59) found that psilocybin produced superior improvements in cognitive biases. Psilocybin significantly increased self-reported optimism (d=1.1) and optimistic beliefs about desirable life events (d=1.1), while improving all three domains of dysfunctional attitudes (achievement, dependency, and self-control). Escitalopram showed more modest effects, reducing pessimism about negative events and improving only the achievement domain of dysfunctional attitudes.

Published
Journal
European Neuropsychopharmacology
Authors
Henry, J., Giribaldi, B., Nutt, D. J., Erritzoe, D., Carhart-Harris, R., Lyons, T.
Paywallindividual

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial

This first RCT (n=25) of vaporised DMT (60mg) demonstrated that DMT significantly increased subjective experience measures while causing only transient, safe physiological changes and predominantly mild adverse events. This suggests that inhaled DMT is safe, well-tolerated, and effective at inducing profound altered states of consciousness. Significant correlations were observed between physiological responses and subjective experiences.

Published
Journal
European Neuropsychopharmacology
Authors
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Ruschi Silva, S., Pantrigo, E. J., Medina, M., Arichelle, F., Almeida, R., Aires, R., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Thie, K., Silva-Costa, N., Araújo, D. B., de Araujo Costa Neto, L. A., Lima de Queiroz, M. V. J., Galvão-Coelho, N. L., Palhano-Fontes, F.
Paywallmeta

Do classic psychedelics increase the risk of seizures? A scoping review

This scoping review (s=27) assesses the relationship between classic psychedelics and seizures. It finds that psychedelics may not increase seizure risk in healthy individuals or animals without other drugs, but concomitant use of substances like kambo or lithium could heighten the risk.

Published
Journal
European Neuropsychopharmacology
Authors
Soto-Angona, Ó., Fortea, A., Fortea, L., Martínez-Ramírez, M., Santamarina, E., López, F. J. G., Knudsen, G. M., Ona, G.

Quick Facts

Papers Indexed
32
h-Index
136
Open Access
No
Publisher
Elsevier
Country
Netherlands
Website
Visit